Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations

You may be eligible if

• PROTOCOL ENTRY CRITERIA:
• -Disease Characteristics--
• Diagnosis of macrocystic lymphangioma of the head and/or neck Cystic spaces at least 2.0 mL confirmed by radiographic imaging (MRI or CT) Mixed lymphangiomas (macrocystic and microcystic disease) allowed if macrocystic component comprises at least 50% of the total disease burden
• No mixed hemangioma-lymphangioma lesions
• At least 6 months since prior surgery for lymphangioma
• -Patient Characteristics--
• Hematopoietic: No clinically significant hematologic disease No hemodynamic instability
• Hepatic: No clinically significant hepatic disorder
• Renal: No clinically significant renal disease No personal or family history of post-streptococcal glomerulonephritis
• Cardiovascular: No personal or family history of rheumatic heart disease
• Pulmonary: No respiratory failure
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• No history of allergy to penicillin
• No concurrent temperature of 100.5 degrees or greater
• No active upper respiratory infection
• No personal or family history of obsessive-compulsive or tic disorders
• No personal or family history of PANDA (pediatric autoimmune neuro- psychiatric disorder associated with streptococcal infections)
• No history of hypersensitivity to iodine, Omnipaque, or gadolinium (if fluoroscopy is considered necessary)
• No history of poor health (including congenital disorders, chronic diseases, or immunologic dysfunction)